Not provided
Not provided
Not provided
Not provided
Lack of funding
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Max Planck Institute for Metabolism Research | OTHER |
Not provided
Not provided
Not provided
Different compounds that might modify the glucose regulation in the central nervous system will be evaluated in healthy volunteers. Several examinations will be performed in order to get a detailed plan how these substances might work.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Intranasal Insulin | Experimental | Intranasal administered insulin |
|
| Cannabidiol CR | Experimental | Cannabidiol is the main non psychoactive compound of the Cannabis sativa plant. |
|
| URB597 | Experimental | URB597 is a selective inhibitor of the Fatty acid amide hydrolase enzyme. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| URB597 | Drug | 10 mg / d for 5 days, orally |
| |
| intranasal Insulin |
| Measure | Description | Time Frame |
|---|---|---|
| Clinical assessment with several psychopathological scores for self-assessment and peer evaluation (BPRS, PANSS, SIPS, CGI, MADRS, HAM-A, SCL-90-R) | Seven days | |
| Laboratory assessment (routine testing, "-omics", genetic analyses, endocannabinoid levels) | Seven days | |
| Diagnostics of the cerebrospinal fluid | Seven days | |
| fMRI scan of the brain | Seven days |
| Measure | Description | Time Frame |
|---|---|---|
| Regular evaluating of the subject's condition and ability to continue the study by CGI | Seven days | |
| Regular laboratory testing and ECG | Seven days | |
| Scales for the assessment of adverse events (UKU, SCL- 90-R) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| F. Markus Leweke, MD | Central Institute of Mental Health | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Dep. of Psychiatry and Psychotherapy, Central Institute of Mental Health | Mannheim | Baden-Wurttemberg | 68159 | Germany |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D012559 | Schizophrenia |
| ID | Term |
|---|---|
| D019967 | Schizophrenia Spectrum and Other Psychotic Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| C500528 | cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Drug |
160 IU / d for 5 days, intranasal |
|
| Cannabidiol CR | Drug | 320 mg / d for 5 days, orally |
|
|
| Seven days |
| (Numbers of) SAE and AE | Seven days |